Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Afatinib Shows Safety and Efficacy Among Elderly

Publish date:: May 7, 2019

Key clinical point: Afatinib appears safe and effective for elderly patients with non–small cell lung cancer.

Major finding: Elderly patients had 12-month progression-free survival rate of 62%.

Study details: A retrospective analysis of the GIDEON phase 3 trial.

Disclosures: Boehringer Ingelheim funded the study. The investigators did not report conflicts of interest.

Citation:

Brückl et al. ELCC 2019. Abstract 125P.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Lung Cancer

Two different radiation boost strategies reduce local failures in NSCLC,

Rechallenge ‘reasonable’ for some with small-cell lung cancer,

Black patients with ES-SCLC get less chemo but have better survival,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Reduced cancer mortality with Medicaid expansion,